View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 30, 2018updated 01 Aug 2018 7:38am

FIND concludes RFP process to address diagnostic needs for HCV

The Foundation for Innovative New Diagnostics (FIND) has concluded an extensive Request for Proposal (RFP) process to address the diagnostic requirements for hepatitis C virus (HCV).

T he Foundation for Innovative New Diagnostics (FIND) has concluded an extensive Request for Proposal (RFP) process to address the diagnostic requirements for the hepatitis C virus (HCV).

Grants will be awarded to carry out feasibility studies of several technologies that could transform HCV testing at the point of care (POC).

BLINK-DX, Abbott , and Diagnostics for the Real World will get grant support to advance their potential HCV RNA tests on a polyvalent, POC molecular platform.

Chembio Diagnostics, Mologic and DCN Diagnostics will also get support to develop and validate prototype HCV core antigen (cAg) tests on their rapid diagnostic test (RDT ) platforms.

“Grants will be awarded to carry out feasibility studies of several technologies that could transform HCV testing at the point of care.”

Besides the funding, FIND will offer project support, including technical expertise, reference samples for assay development, and antibodies for capture and detection of HCV cAg.

T his RFP comes following an extensive round of consultations by FIND with several stakeholders, which led to the development of a target product profile (T PP) with an intention to facilitate the decentralisation of differentiated HCV care and treatment services, as suggested in the guidelines of the World Health Organization (WHO) for hepatitis B and C testing.

FIND has given grants to Delhi Network of Positive People (DNP+) and T reatment Action Group (T AG) for the development and implementation of country-specific strategies for demand creation and advocacy activities on HCV diagnosis and diagnostics in Cameroon, Georgia, India, Malaysia, Myanmar and Viet Nam.

T he feasibility studies and the demand creation and advocacy programmes are both part of the Unitaid-funded Hepatitis C Elimination through Access to Diagnostics (HEAD-Start) project.

HCV is an infectious disease, claiming the lives of around 400,000 people every year.

More than 71 million people are chronically infected, and over 80% of them live in low and middle-income countries (LMICs). However, only one in five people know they have the disease.

WHO has set a target of eliminating viral hepatitis by 2030.

FIND CEO Catharina Boehme said: “Chronic hepatitis C has surpassed HIV as a leading cause of death in many countries, but to achieve WHO elimination targets – and to avoid a potential 2.1 million HCV-associated deaths – it is crucial to increase the number of people who are diagnosed and link them to treatment.

“We need affordable, point-of-care diagnostics, and smart strategies to ensure they reach patients, including integration into existing testing pathways such as HIV care and support services. Without this holistic diagnostic approach, we will not succeed.”

Related Companies

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network